KPV
A three-amino-acid fragment of alpha-MSH that delivers targeted NF-κB anti-inflammatory action without the parent hormone's tanning, appetite, or arousal effects.
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), one of the smallest bioactive peptides in research at ~342 Da. It retains the parent hormone's anti-inflammatory activity while shedding the melanocortin receptor pharmacology responsible for pigmentation, appetite suppression, and arousal. KPV is taken up into inflamed cells via the PepT1 oligopeptide transporter, where it inhibits NF-κB signaling and reduces pro-inflammatory cytokine output. Its preclinical evidence base in inflammatory bowel disease and skin inflammation is substantial, but human clinical trials are essentially absent and it holds no regulatory approval anywhere.
Class
Synthetic tripeptide (α-MSH C-terminal fragment)
Half-life
Short plasma half-life (~15–30 minutes); PepT1-mediated cellular uptake extends functional anti-inflammatory activity in target tissue
Routes
Oral, Subcutaneous, Topical, Intranasal, Rectal
Category
Healing & Recovery
Researched benefits
What it's studied for
Potent anti-inflammatory activity
KPV inhibits NF-κB—the master transcription factor for inflammation—reducing production of TNF-α, IL-1β, IL-6, and IL-8 across intestinal epithelial cells, macrophages, T cells, and keratinocytes. Effects are seen at nanomolar to picomolar concentrations in cell culture, dampening inflammatory activation without broad immunosuppression.
Gut healing and barrier repair
In colitis models KPV reduces colonic inflammation and helps preserve epithelial tight-junction proteins (occludin, ZO-1, claudins) that maintain gut barrier integrity. Because PepT1 is upregulated on inflamed intestinal tissue, oral KPV self-targets to the site of inflammation—a rare property for a peptide drug.
Skin and wound healing support
Topical KPV has shown reduced inflammation, scratching behavior, and lesion severity in preclinical models of atopic dermatitis, psoriasis-like disease, and contact dermatitis, with accelerated skin barrier repair in wound-healing models. Human evidence is limited to small case series.
No pigmentation or melanocortin side effects
As only the C-terminal tail of α-MSH, KPV lacks the N-terminal sequence that activates MC1R (pigmentation) and MC4R (appetite/arousal), so it does not cause tanning, mole darkening, appetite suppression, or the erectile effects of analogs like Melanotan II and PT-141.
Mast cell stabilization
In allergic inflammation models—asthma, atopic dermatitis, rhinitis—KPV reduces mast cell degranulation and histamine release, partly through NF-κB inhibition and partly through effects on IgE-mediated activation, supporting its study as a topical agent for allergic skin conditions.
Anti-cancer research interest
In colitis-associated colorectal cancer models, PepT1-mediated KPV delivery reduced mucosal inflammation and attenuated inflammatory signaling in tumor-adjacent tissue. This interest is strictly preclinical—KPV is not studied or used as a cancer treatment.
Mechanism
How it works
KPV is unusual among peptides in that it does not act primarily through cell-surface G-protein-coupled receptors. Instead it is imported into target cells by PepT1 (SLC15A1), a proton-coupled oligopeptide transporter that normally absorbs dietary di- and tri-peptides. Under inflammatory conditions—ulcerative colitis, Crohn's disease, DSS colitis—PepT1 is dramatically upregulated on inflamed colonic epithelium and on activated macrophages and lymphocytes, so KPV is pulled preferentially into inflamed tissue while healthy tissue largely ignores it. This 'endogenous targeting' is why orally administered KPV can concentrate at the site of gut inflammation despite a short plasma half-life.
Once inside the cell, KPV's principal documented effect is inhibition of NF-κB, the master transcription factor for inflammation. It interferes at multiple points—reduced IκB degradation, reduced p65 nuclear translocation, and reduced DNA binding of the active NF-κB dimer. The downstream result is markedly lower transcription of pro-inflammatory genes: TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS and others. Across cell types the theme is consistent—KPV dampens the amplitude of activated inflammatory responses without killing immune cells or shutting down all cytokine production.
KPV also preserves intestinal tight-junction function and stabilizes mast cells, reducing degranulation and histamine release in allergic models. Although KPV does not primarily signal through melanocortin receptors, some studies report low-affinity MC1R modulation in skin cells that may contribute minorly to its topical anti-inflammatory effect. Crucially it does not meaningfully activate MC1R (pigmentation) or MC4R (appetite/arousal), which is why it lacks the side-effect profile of full α-MSH and melanotan analogs.
Pharmacokinetically, KPV is cleared rapidly from plasma by peptidases and renal filtration (half-life on the order of minutes), but the PepT1-mediated cellular uptake means it lingers inside target cells longer than plasma levels suggest—explaining durable anti-inflammatory activity from oral dosing. Nanoparticle and nanofiber formulations that protect KPV from intestinal peptidases and deliver it to colonic PepT1 sites are an active area of research. Because its mechanism is NF-κB inhibition rather than receptor-level signaling, KPV stacks cleanly with mechanism-distinct repair peptides such as BPC-157 and TB-500.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
For subcutaneous, intranasal, or rectal use, reconstitute a 10 mg lyophilized vial with 2 mL bacteriostatic water for a 5 mg/mL solution (500 mcg = 0.1 mL / 10 units on a 100-unit insulin syringe; 1 mg = 0.2 mL / 20 units). An alternative 1 mL diluent gives 10 mg/mL for higher doses or smaller injection volumes. Add water down the vial wall, swirl gently (do not shake), and store the reconstituted solution refrigerated at 2–8°C for 28–30 days protected from light—do not freeze reconstituted solution. Topical creams (0.05–0.5%) are best prepared by a compounding pharmacy.
Beginner
- Dose
- 500 mcg per dose
- Frequency
- Once daily
- Timing
- Morning or early afternoon, empty stomach with water
- Duration
- 6–8 weeks, then a 2–4 week break
- Route
- Oral capsule or sublingual troche
Week 1 confirms tolerance (most users notice nothing); increase to 1 mg daily in weeks 2–3 if targeting more pronounced inflammation. Evaluate signal by week 4.
Intermediate
- Dose
- 1–2 mg daily oral (divided BID), or 500 mcg–1 mg daily subcutaneous
- Frequency
- Once daily or divided BID/TID
- Timing
- Empty stomach for oral; morning standard for SubQ (KPV has no strong circadian effect)
- Duration
- 8–12 weeks continuous, then a 4-week break
- Route
- Oral, sublingual, subcutaneous, or oral + topical combination
For established gut inflammation, oral (ideally delayed-release) targets colonic PepT1; SubQ favors systemic/non-gut targets. Optional intranasal 200–400 mcg daily for airway or sinus inflammation.
Advanced
- Dose
- 2–5 mg daily oral (divided TID–QID), 1–2 mg daily SubQ, or 1–2 mg rectal retention enema
- Frequency
- Divided dosing for steady-state exposure
- Timing
- Route- and condition-specific; rectal administered nightly
- Duration
- Biomarker-driven or 4-week intensive phases with step-down; periodic breaks
- Route
- High-dose oral, SubQ, rectal, intranasal, or topical
About route/formulation sophistication, not dose escalation—NF-κB inhibition saturates. Human dosing data max out at 1–2 mg oral; 5+ mg is community practice without published human safety data. Do not exceed 5 mg/day without specific indication.
- KPV does not have a linear dose-response curve—NF-κB inhibition saturates at modest concentrations, so most responders see adequate effects at 500 mcg–1 mg daily oral, with 2 mg reserved for partial responders and aggressive targets.
- Estimated bioavailability by route: oral 10–20%, sublingual 20–30%, subcutaneous 60–80%, intranasal variable (5–40%).
- Oral KPV is best taken on an empty stomach (30 min before or 2+ hours after a meal) to minimize peptidase degradation.
- Effects are gradual, not immediate: gut changes often appear in 3–4 weeks, skin in 2–3 weeks, and inflammatory markers (CRP/ESR) in 4–8 weeks. If no change after 6–8 weeks, KPV is likely not the right intervention.
- Community practice cycles KPV (breaks every cycle, and every 6–12 months for sustained users) as a precaution, since there is no long-term human safety data—KPV has no documented tolerance/tachyphylaxis.
- Verify a Certificate of Analysis showing ≥98% HPLC purity and mass-spec confirmation (expected MW ~342 Da) before use.
- Stop KPV 7–14 days before elective surgery and resume 2–4 weeks postoperatively if uncomplicated.
Evidence
Research & clinical studies (4)
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
In intestinal cell cultures and mouse colitis models, KPV was transported into cells via the PepT1 di/tripeptide transporter and inhibited NF-κB and MAP kinase pathways at nanomolar concentrations, with oral KPV reducing severity in DSS- and TNBS-induced colitis.
PMID 18061177Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
In a mouse ulcerative colitis model, KPV encapsulated in hyaluronic acid-functionalized nanoparticles delivered orally in a hydrogel significantly reduced mucosal damage and TNF-α expression versus free KPV nanoparticles, demonstrating targeted colonic delivery.
PMID 28143741Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells
KPV reduced lipid accumulation in liver cells by decreasing oxidative stress and suppressing fatty acid synthase expression via the PPARγ pathway, suggesting a mechanism by which it could influence hepatic steatosis.
PMID 42064835A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
A critical review of peptide and peptide-analog drug use in sport and bodybuilding that includes KPV among discussed anti-inflammatory research peptides.
PMID 41880199Combinations
Stacking & blends
Gut Healing Stack
Combine inflammation control with epithelial repair and tissue remodeling for gut and connective-tissue recovery
The three mechanisms are distinct and non-overlapping—KPV quenches NF-κB-driven inflammation, BPC-157 promotes epithelial repair and angiogenesis, and TB-500 drives cell migration and matrix remodeling—so additive benefit is plausible. Typical: oral KPV 500 mcg–1 mg daily, BPC-157 500 mcg oral/SubQ BID, TB-500 2–5 mg SubQ weekly for 6–8 weeks. No negative interactions reported, but no controlled human trials of the stack exist.
KPV + Larazotide: Gut Barrier & Anti-Inflammatory
Support gut barrier integrity while managing mucosal inflammatory signaling
KPV provides MC1R/NF-κB-mediated anti-inflammatory action in the GI tract while larazotide acetate (AT-1001) acts as a tight-junction regulator that reduces intestinal permeability, combining barrier repair with inflammation control.
Skin Inflammation Combination
Manage localized inflammatory skin conditions such as eczema
Topical KPV 0.1–0.2% BID quenches skin inflammation via NF-κB inhibition and mast cell stabilization, paired with topical GHK-Cu for copper-peptide wound-healing and remodeling signaling.
KLOW Blend
Broad healing, recovery, and anti-inflammatory support
KPV is one of the four components of the KLOW blend used in clinical-pharmacy practice, contributing its NF-κB anti-inflammatory action alongside the tissue-repair and remodeling mechanisms of the other peptides.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Known hypersensitivity to KPV or formulation excipients (including benzyl alcohol in bacteriostatic water for injectables)
- Pregnancy and lactation (no human safety data)
- Active untreated serious infection (KPV's anti-inflammatory action may blunt needed immune response)
- Hematologic malignancies under active treatment (NF-κB is often a disease driver or therapeutic target)
- Solid tumor history within 5 years or active solid tumor (use only with oncology consultation)
- Autoimmune disease managed on biologics/JAK inhibitors (additive immunosuppression—specialist oversight required)
- History of recurrent infections (approach conservatively)
- Children and adolescents under 18 (no pediatric safety data)
KPV's safety profile in preclinical studies and available research use has been favorable, with no serious adverse events reported in the published literature and a low side-effect burden consistent with its small size and α-MSH origin. Long-term (>1 year continuous) human safety is uncharacterized. The main theoretical concern is additive immunosuppression when combined with corticosteroids, biologics, or JAK inhibitors. KPV is compatible with NSAIDs, acetaminophen, anticoagulants, GLP-1 agonists, growth hormone secretagogues, and common healing peptides. The biggest real-world risk is using KPV as a substitute for appropriate medical care for serious inflammatory disease.
FAQ
KPV — common questions
What is KPV and how does it differ from alpha-MSH?
KPV is a three-amino-acid peptide (Lysine-Proline-Valine) that forms the C-terminal tail of alpha-MSH. While full-length alpha-MSH (13 amino acids) produces pigmentation, appetite, and arousal effects through melanocortin receptors, KPV retains the anti-inflammatory activity via NF-κB inhibition without those other effects—it lacks the N-terminal sequence responsible for MC1R and MC4R activation.
Does KPV work orally, or do I need to inject it?
KPV is one of the few research peptides with documented oral activity. It is absorbed via the PepT1 transporter, which is upregulated on inflamed gut tissue, so oral KPV can concentrate at the site of gut inflammation. Most users start with oral dosing for simplicity; subcutaneous injection provides higher systemic bioavailability for skin, joint, or airway targets.
Will KPV make me tan like Melanotan?
No. The pigmentation effect of alpha-MSH and Melanotan II comes from the N-terminal sequence binding MC1R on melanocytes. KPV is only the C-terminal tripeptide tail and lacks that sequence. Over 20+ years of use, published studies and community reports describe no pigmentation changes or mole darkening. Any pigmentation from a product labeled KPV would suggest contamination.
Can KPV help with ulcerative colitis or Crohn's disease?
Preclinical evidence in DSS- and TNBS-colitis models consistently shows KPV reduces disease activity, histological damage, and colonic cytokines, and its NF-κB inhibition plus tight-junction preservation are directly relevant to IBD. However, human evidence is limited to small case series. KPV should not replace established IBD therapy in moderate-to-severe disease; it may be a physician-directed adjunct.
How long does it take to see results with KPV?
KPV is slow-acting with no immediate subjective effects. Gut-related changes often appear in 3–4 weeks, skin changes in 2–3 weeks, and reductions in inflammatory markers (CRP, ESR) in 4–8 weeks. If there is no change after 6–8 weeks of consistent dosing, KPV is probably not the right intervention for your situation.
Is it safe to stack KPV with BPC-157 and TB-500?
This is the most common KPV stacking pattern (the 'gut healing stack'). The three mechanisms are distinct—KPV suppresses inflammation, BPC-157 supports repair and angiogenesis, TB-500 drives cell migration—so additive benefit is plausible and no negative interactions have been reported. Controlled human trials of the specific stack do not exist; introduce compounds one at a time to attribute effects.
Is KPV FDA approved or legal?
KPV has no FDA approval for any indication. It is legal to purchase as a research chemical in most jurisdictions but is not approved for human consumption. It was removed from the FDA's Category 2 503A bulk substances list on April 22, 2026 and scheduled for PCAC review on July 23, 2026—a compounding-status question, not therapeutic approval.
What is the biggest risk of KPV use?
The biggest real-world risk is not a direct side effect—KPV is well-tolerated—but using it as a substitute for appropriate medical care and delaying diagnosis of serious inflammatory disease. Secondary risks are poor sourcing (verify ≥98% HPLC purity COAs) and additive immunosuppression if already on prescription anti-inflammatory therapy.
